Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2022 | PerELISA: overexpression of 13 genes associated with endocrine sensitivity in HR+/HER2+ BC

Gaia Griguolo, MD, University of Padova, Padova, Italy, discusses the characterization of genomic features associated with endocrine sensitivity in a the translational of the Phase II PerELISA (NCT02411344) trial. The Phase II trial assessed the activity of de-escalated neoadjuvant pertuzumab plus trastuzumab in combination with letrozole without chemotherapy in patients with HR-positive/HER2-positive (HR+/HER2+) breast cancer. In the translational analysis, the expression of 555 genes was evaluates at baseline from 56 patients. 13 genes were identified to be overexpressed in endocrine-sensitive breast cancer, compared to non-endocrine sensitive. RB loss signature was also evaluated, and found to be associated with higher pathologic complete response (pCr) rates in triple-positive breast cancer. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.